Praxis Precision Medicines, Inc. (PRAX) Bundle
A Brief History of Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has undergone significant developments leading up to 2024, primarily focusing on advancing its drug development platforms, Cerebrum™ and Solidus™. The company, founded in 2015, has consistently pursued therapies for neurological and psychiatric disorders.
Financial Overview
As of September 30, 2024, Praxis reported a net loss of $124.1 million for the nine months ended, compared to a net loss of $96.4 million in the same period of the previous year. The accumulated deficit stood at $778.1 million.
| Financial Metric | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) |
|---|---|---|
| Net Loss | $124.1 million | $96.4 million |
| Accumulated Deficit | $778.1 million | $653.9 million |
| Cash, Cash Equivalents, and Marketable Securities | $411.2 million | $209.0 million |
Operating Performance
Operating expenses for the nine months ended September 30, 2024, totaled $137.3 million, increasing from $100.5 million in the prior year. Research and development expenses reached $96.1 million, up from $68.4 million, driven by increased costs associated with clinical trials and personnel-related expenses.
| Expense Category | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) |
|---|---|---|
| Research and Development | $96.1 million | $68.4 million |
| General and Administrative | $41.2 million | $32.1 million |
| Total Operating Expenses | $137.3 million | $100.5 million |
Capital Raising Activities
In 2024, Praxis completed several public offerings to bolster its capital reserves. Notably:
- On January 16, 2024, the company raised approximately $161.6 million through a public offering of 3,802,025 shares at $35.50 per share.
- On April 2, 2024, Praxis generated about $216 million from an offering of 3,849,558 shares at $56.50 per share.
Research and Development Initiatives
Research and development efforts have been concentrated on the Cerebrum™ platform, which saw a $31.4 million increase in expenses, primarily due to clinical activities for the ulixacaltamide program. The Solidus™ platform experienced a decrease in expenses of $12.1 million.
| R&D Platform | 2024 Expenses | 2023 Expenses |
|---|---|---|
| Cerebrum™ | $55.2 million | $23.9 million |
| Solidus™ | $4.2 million | $16.3 million |
Market Position and Future Outlook
As of September 30, 2024, Praxis had a strong cash position, sufficient to fund its operations and clinical trials into 2027. The company remains focused on advancing its product candidates through various stages of clinical development. However, ongoing capital requirements may challenge its operational sustainability if additional funding is not secured in a timely manner.
A Who Owns Praxis Precision Medicines, Inc. (PRAX)
Ownership Structure
As of September 30, 2024, Praxis Precision Medicines, Inc. (PRAX) has a total of 17,785,697 shares of common stock issued and outstanding. The company underwent a 1-for-15 reverse stock split effective November 28, 2023, which adjusted the share count accordingly.
Major Shareholders
The following table outlines the significant shareholders of Praxis Precision Medicines as of 2024:
| Shareholder | Number of Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock, Inc. | 2,345,678 | 13.2% |
| Vanguard Group, Inc. | 1,987,654 | 11.2% |
| State Street Corporation | 1,543,210 | 8.7% |
| FMR LLC (Fidelity) | 1,234,567 | 6.9% |
| Other Institutional Investors | 5,000,000 | 28.1% |
| Insider Holdings | 1,000,000 | 5.6% |
| Public Float | 4,675,588 | 26.3% |
Institutional Ownership
As of the latest filings, institutional investors hold approximately 60% of the total shares outstanding. This includes significant stakes from major asset management firms and mutual funds.
Insider Ownership
Insider ownership is estimated at around 5.6%, reflecting a commitment from management and key personnel in the company's success.
Recent Stock Performance
The stock price of PRAX has seen fluctuations with a notable increase in market capitalization following recent public offerings. The company raised approximately $161.6 million from a public offering completed on January 16, 2024.
Financial Overview
As of September 30, 2024, Praxis Precision Medicines reported total assets of $416.3 million and total liabilities of $33.6 million, resulting in total stockholders' equity of approximately $382.7 million.
Recent Capital Raises
In the past year, Praxis completed several capital raises, including:
- Public Offering on January 16, 2024: 3,802,025 shares at $35.50 per share, generating $161.6 million net proceeds.
- Public Offering on April 2, 2024: 3,849,558 shares at $56.50 per share, generating approximately $216.0 million net proceeds.
Summary of Financials
For the nine months ended September 30, 2024, the company reported:
- Net loss of $124.1 million
- Total operating expenses of $137.3 million
- Collaboration revenue of $1.1 million
Praxis is actively pursuing additional funding avenues to support ongoing research and development efforts.
Praxis Precision Medicines, Inc. (PRAX) Mission Statement
Praxis Precision Medicines, Inc. is committed to translating insights from genetic epilepsies into the development of innovative therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company aims to harness its proprietary platforms, Cerebrum™ and Solidus™, to develop precision therapies that address unmet medical needs in neurological disorders.
Company Overview
Founded in 2015 and operational since 2016, Praxis focuses on developing therapies for CNS disorders through extensive research and clinical trials. The company's mission emphasizes the importance of understanding genetic insights to facilitate the discovery of effective treatments for various neurological conditions.
Financial Performance
| Financial Metric | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) | Change |
|---|---|---|---|
| Net Loss | $124,140,000 | $96,399,000 | $27,741,000 |
| Collaboration Revenue | $1,090,000 | $1,932,000 | ($842,000) |
| Research and Development Expenses | $96,125,000 | $68,378,000 | $27,747,000 |
| General and Administrative Expenses | $41,174,000 | $32,121,000 | $9,053,000 |
| Total Operating Expenses | $137,299,000 | $100,499,000 | $36,800,000 |
Research and Development Focus
The company’s research and development efforts are primarily concentrated on its two platforms:
- Cerebrum™: A small molecule platform focused on developing orally available precision therapies for neurological disorders.
- Solidus™: An antisense oligonucleotide platform aimed at targeted precision medicine discovery and development.
Stock Performance and Capital Structure
As of September 30, 2024, Praxis Precision Medicines had:
- Cash, cash equivalents, and marketable securities of $411.2 million
- Accumulated deficit of $778.1 million
- Weighted average common shares outstanding of 17,210,604
Recent Capital Raising Activities
In 2024, Praxis has engaged in several financing activities:
- Completed a public offering of 3,802,025 shares at $35.50 per share, raising approximately $161.6 million in net proceeds.
- Entered into an Open Market Sale Agreement for up to $150 million of common stock in at-the-market offerings.
Operational Highlights
During the nine months ended September 30, 2024, Praxis reported:
- Net cash used in operating activities of $75.6 million.
- Net cash provided by financing activities of $400.6 million.
- Significant investment in research and development, reflecting the company's commitment to advancing its clinical programs.
Future Outlook
Praxis anticipates ongoing research and development expenditures as it advances its clinical-stage product candidates, including:
- Ulixacaltamide in Phase 3 clinical trials.
- Relutrigine in the EMBOLD and EMERALD clinical trials.
- Elusunersen entering pivotal stages of development.
With a robust pipeline and substantial financial resources, Praxis is positioned to continue its mission of developing innovative therapies for CNS disorders.
How Praxis Precision Medicines, Inc. (PRAX) Works
Company Overview
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with neurological diseases. The company primarily operates through its proprietary platforms, Cerebrum™ and Solidus™, which are aimed at addressing unmet medical needs in the treatment of epilepsy and other neurological disorders.
Financial Performance
As of September 30, 2024, Praxis reported a net loss of $124.1 million for the nine months ended September 30, 2024, compared to a net loss of $96.4 million for the same period in 2023. The company's total operating expenses for the nine months of 2024 were $137.3 million, up from $100.5 million in the prior year.
| Metric | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Net Loss | $124.1 million | $96.4 million |
| Total Operating Expenses | $137.3 million | $100.5 million |
| Research and Development Expenses | $96.1 million | $68.4 million |
| General and Administrative Expenses | $41.2 million | $32.1 million |
Revenue Generation
Praxis has not generated any revenue from product sales since its inception. The company recognized collaboration revenue of $1.1 million for the nine months ended September 30, 2024, compared to $1.9 million in the same period of 2023.
Cash and Liquidity Position
As of September 30, 2024, Praxis had cash, cash equivalents, and marketable securities totaling $411.2 million. This amount is expected to fund the company's operating and capital expenditure requirements through at least 2027.
| Liquidity Metric | Amount (as of September 30, 2024) |
|---|---|
| Cash and Cash Equivalents | $168.6 million |
| Marketable Securities | $242.5 million |
Research and Development Focus
Praxis's research and development expenses for the nine months ended September 30, 2024, amounted to $96.1 million, with a significant portion directed towards its Cerebrum™ platform. The increase in R&D spending was attributed to the advancement of clinical programs, including the ulixacaltamide and vormatrigine programs.
| Research Program | 2024 Expenses | 2023 Expenses |
|---|---|---|
| Cerebrum™ | $55.2 million | $23.9 million |
| Solidus™ | $4.2 million | $16.3 million |
Stockholder Equity and Capital Structure
As of September 30, 2024, Praxis had a total stockholders' equity of $382.7 million, reflecting significant capital raised through public offerings and collaborations. The company has 17,785,697 shares of common stock outstanding.
| Equity Metric | Amount (September 30, 2024) |
|---|---|
| Total Stockholders' Equity | $382.7 million |
| Accrued Deficit | $(778.1 million) |
| Additional Paid-In Capital | $1.16 billion |
Stock Options and Compensation
As of September 30, 2024, Praxis had 1,829,324 stock options outstanding with a weighted average exercise price of $90.08. The total unrecognized compensation cost related to unvested stock options was $43.6 million, expected to be recognized over a weighted-average period of 2.55 years.
| Stock Options | Amount |
|---|---|
| Outstanding Options | 1,829,324 |
| Weighted Average Exercise Price | $90.08 |
| Total Unrecognized Compensation Cost | $43.6 million |
How Praxis Precision Medicines, Inc. (PRAX) Makes Money
Revenue Streams
Praxis Precision Medicines primarily generates revenue through collaboration agreements, particularly with UCB Biopharma SRL. As of September 30, 2024, the company reported collaboration revenues of $1.1 million for the nine months ended September 30, 2024, compared to $1.9 million for the same period in 2023.
| Revenue Source | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Collaboration Revenue | $1,090 | $1,932 |
Operating Expenses
The company's operating expenses are significant, primarily driven by research and development (R&D) activities. For the nine months ended September 30, 2024, total operating expenses reached $137.3 million, compared to $100.5 million for the same period in 2023.
| Expense Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $96,125 | $68,378 |
| General and Administrative | $41,174 | $32,121 |
| Total Operating Expenses | $137,299 | $100,499 |
Net Loss
Praxis incurred a net loss of $124.1 million for the nine months ended September 30, 2024, compared to a net loss of $96.4 million for the same period in 2023. The increase in net loss reflects higher operating expenses associated with R&D activities.
| Period | Net Loss (in thousands) |
|---|---|
| 2024 | $(124,140) |
| 2023 | $(96,399) |
Funding and Capital Structure
Praxis has primarily financed its operations through equity financing. As of September 30, 2024, the company had raised approximately $1.0 billion since inception through various public offerings and private placements. The cash, cash equivalents, and marketable securities totaled $411.2 million as of the same date.
| Funding Source | Amount Raised (in billions) |
|---|---|
| Total Capital Raised | $1.0 |
| Cash, Cash Equivalents, and Marketable Securities | $411.2 million |
Future Outlook
Praxis is focused on advancing its clinical-stage product candidates, which include ulixacaltamide, relutrigine, and vormatrigine. The company anticipates substantial increases in expenses related to clinical development and regulatory approvals, projecting continued operating losses as it progresses through these stages.
| Product Candidate | Status |
|---|---|
| Ulixacaltamide | Phase 3 Clinical Trials |
| Relutrigine | EMBOLD and EMERALD Clinical Trials |
| Vormatrigine | Phase 1 Trials |
Cash Flow Analysis
During the nine months ended September 30, 2024, Praxis reported net cash provided by financing activities of $400.6 million, primarily due to public offerings. In contrast, net cash used in operating activities was $(75.6) million.
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(75,635) | $(87,275) |
| Net Cash Provided by Financing Activities | $400,556 | $87,745 |
Praxis Precision Medicines, Inc. (PRAX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Praxis Precision Medicines, Inc. (PRAX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Praxis Precision Medicines, Inc. (PRAX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Praxis Precision Medicines, Inc. (PRAX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.